Alkeon Capital Management
BCRX icon

Alkeon Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Alkeon Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,464,021
Closed -$41.5M – 116
2025
Q3 		$41.5M Sell
5,464,021
-250,000
-4% -$2.08M 0.06% 87
2025
Q2 		$51.2M Sell
5,714,021
-1,500,000
-21% -$14M 0.09% 76
2025
Q1 		$54.1M Buy
7,214,021
+120,199
+2% +$970K 0.11% 71
2024
Q4 		$53.3M Hold
7,093,822
– – 0.11% 69
2024
Q3 		$53.9M Sell
7,093,822
-5,662
-0.1% -$43K 0.09% 74
2024
Q2 		$43.9M Buy
7,099,484
+3,000,000
+73% +$16.6M 0.07% 80
2024
Q1 		$20.8M Buy
4,099,484
+2,430,000
+146% +$13.7M 0.04% 86
2023
Q4 		$10M Sell
1,669,484
-2,829
-0.2% -$16.4K 0.02% 87
2023
Q3 		$11.8M Hold
1,672,313
– – 0.02% 91
2023
Q2 		$11.8M Buy
1,672,313
+403,461
+32% +$3.24M 0.02% 103
2023
Q1 		$10.6M Sell
1,268,852
-216,965
-15% -$2.09M 0.02% 110
2022
Q4 		$17.1M Buy
1,485,817
+20,532
+1% +$256K 0.07% 110
2022
Q3 		$18.5M Buy
1,465,285
+296,940
+25% +$3.82M 0.06% 114
2022
Q2 		$12.4M Sell
1,168,345
-19,500
-2% -$201K 0.03% 121
2022
Q1 		$19.3M Buy
+1,187,845
New +$19.1M 0.04% 124

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Alkeon Capital Management's BCRX Position: Q4 2025 in Review

Alkeon Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 5,464,021 shares — an estimated $41.5M sold.

Alkeon Capital Management first reported a position in BCRX in Q1 2022 and held it in 15 quarters. The position peaked at $54.1M in Q1 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Alkeon Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Alkeon Capital Management sold 5,464,021 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $41.5M.
  • Alkeon Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 15 quarters.
  • Alkeon Capital Management's BioCryst Pharmaceuticals position peaked at $54.1M in Q1 2025.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Alkeon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.